Drug utilization of intrinsa® (testosterone patch) in England: Interim analysis of a prescription-event monitoring study to support risk management

Drug Safety

Volumn 33, Issue 3, 2010, Pages 213-221

  Osborne, Vicki ^a,b   Hazell, Lorna ^a,b   Layton, Deborah ^a,b   Shakir, Saad A W ^a,b  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DRUG INDICATION; DRUG USE; ESTROGEN THERAPY; FEMALE; GENERAL PRACTICE; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; OFF LABEL DRUG USE; OVARIECTOMY; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PRENATAL DRUG EXPOSURE; PRESCRIPTION; PRIORITY JOURNAL; UNITED KINGDOM;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; DRUG PRESCRIPTIONS; DRUG UTILIZATION; ENGLAND; FEMALE; GUIDELINE ADHERENCE; HEALTH SURVEYS; HUMANS; HYPOGLYCEMIC AGENTS; LABORATORY TECHNIQUES AND PROCEDURES; MEDICATION ADHERENCE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS, FAMILY; PRACTICE GUIDELINES AS TOPIC; PRODUCT SURVEILLANCE, POSTMARKETING; RISK MANAGEMENT; TESTOSTERONE; TREATMENT OUTCOME;

EID: 76949105828     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11533720-000000000-00000     Document Type: Article

References (22)

1. Procter & Gamble. Intrinsa: summary of product char-acteristics, Procter & Gamble, 2007 [online]. Available from URL: http://www.ema.europa. eu/humandocs/PDFs/EPAR/intrinsa/H-634-PI-en.pdf [Accessed 2010 Jan 29]
2. EMEA. Intrinsa: European public assessment report. EMA, 2006 [online]. Available from URL: http://www.ema. europa.eu/humandocs/PDFs/EPAR/intrinsa/ 063406en6. pdf [Accessed 2010 Jan 29]
3. Braunstein GD, Sundwell DA, Katz M, et al. Safety and efficacy of a testosterone patch for the treatment of hypo-active sexual desire disorder in surgically menopausal women. Arch Intern Med 2005; 165: 1582-1589
4. Buster JE, Kingsberg SA, Aguirre O, et al. Testosterone patch for sexual desire in surgically menopausal women: a randomised trial. Obstet Gynecol 2005; 105: 944-952
5. Davis SR, van der Morren MJ, van Lunsen RH, et al. Effi-cacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause 2006; 13 (3): 387-396
6. Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000; 343: 682-688
7. Simon J, Braunstein G, Utian W, et al. Testosterone patch increases sexual activity and desire in surgically menopau-sal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005; 90: 5226-5233
8. Davis SR, Moreau M, Kroll R, et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 2008 Nov 6; 359 (19): 2005-2017
9. Shifren JL, Davis SR, Moreau M, et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause 2006; 13 (5): 770-779
10. Martin K, Begaud B, Latry P, et al. Differences between clinical trials and postmarketing use Br J Clin Pharmacol 2004 Jan; 57 (1): 86-92
11. European Commission. Volume 9A of the rules governing medicinal products in the European Union: pharmaco-vigilance for medicinal products for human use. European Commission, 2008 [online]. Available from URL: http://ec.europa.eu/ enterprise/pharmaceuticals/eudralex/vol-9/pdf/vol9a-09-2008.pdf [Accessed 2010 Jan 29]
12. Shakir SAW. Prescription-event monitoring. In: Mann RD, Andrews EB, editors. Pharmacovigilance. 2nd ed. Chiche-ster: John Wiley & Sons Ltd, 2007: 307-316
13. Council for International Organizations of Medical Sciences (CIOMS), World Health Organisation (WHO). International ethical guidelines for biomedical research involving human subjects [online]. Available from URL: http://www.cioms.ch/frame-guidelines-nov-2002.htm [Accessed 2009 Dec 23]
14. Royal College of Physicians of London. Guidelines on the practice of ethics committees in medical research involving human subjects. 3rd ed. London: Royal College of Physicians of London, 1996
15. General Medical Council. Frequently asked questions. Supplement to 'Confidentiality: Protecting and Providing Information'. London: General Medical Council, 2004: 9
16. GlaxoSmithKline. Andropatch: summary of product characteristics. GlaxoSmithKline, 2006 [online]. Available from URL: http://emc.medicines.org.uk/ medicine/2019/SPC/Andropatch+2.5mg/[Accessed 2010 Jan 29]
17. Shufelt C, Braunstein G. Safety of testosterone use in wo-men. Maturitas 2009 May 20; 63 (1): 63-66
18. Lukanova A, Lundin E, Micheli A, et al. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer 2004; 108 (3): 425-432
19. US FDA. Intrinsa medical review. FDA, 2004 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4082B1-02-B-FDA-Intrinsa- Medical-Review.pdf [Accessed 2010 Jan 29]
20. Writing Group for the Women's Health Initiative In-vestigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 2002; 288 (3): 321-333
21. Panzer C, Guay A. Testosterone replacement therapy in naturally and surgically menopausal women. J Sex Med 2009; 6: 8-18
22. Krapf J, Simon J. The role of testosterone in the manage-ment of hypoactive sexual desire disorder in postmeno-pausal women. Maturitas 2009; 63 (3): 213-219